Hongru Li | Brain Metastasis | Best Researcher Award

Dr. Hongru Li | Brain Metastasis | Best Researcher Award

Fuzhou University Affiliated Provincial Hospital | China

Dr. Hongru Li, MD/PhD, is a distinguished clinician-scientist and Chief Physician in the Department of Respiratory and Critical Care Medicine at Fujian Provincial Hospital, Fujian Medical University. With a career dedicated to advancing respiratory medicine and oncology, his expertise lies in lung cancer, metastasis mechanisms, and innovative therapeutic strategies. Over the years, he has combined clinical excellence with groundbreaking research, focusing on molecular pathways and targeted therapies. Dr. Li has published extensively in reputable journals, contributing to understanding brain and bone metastasis in non-small cell lung cancer. His leadership extends to supervising clinical innovation projects funded by national and provincial research grants. Recognized as an outstanding respiratory scholar, he has made notable contributions in translational medicine, bridging laboratory findings with patient care. His research on nanoliposomes, ceramide pathways, and genetic susceptibility in lung cancer exemplifies his commitment to improving treatment outcomes and patient survival in respiratory oncology.

Profile

ORCID

Education

Dr. Hongru Li’s academic foundation is firmly rooted in medicine and specialized respiratory science. He earned his Doctor of Medicine degree at Fujian Medical University, where he developed his core clinical knowledge and interest in pulmonary health. To deepen his expertise, he pursued postgraduate studies in respiratory medicine at Fujian Medical University, gaining hands-on exposure to advanced diagnostic and therapeutic approaches in pulmonary and critical care. His academic journey culminated with a PhD in Respiratory Medicine from Southern Medical University in Guangzhou, where he focused on molecular mechanisms of lung cancer progression and metastasis. His doctoral research provided a solid grounding in translational medicine, integrating clinical insights with cellular and molecular biology. This comprehensive educational background has enabled him to pursue a career balancing patient care with high-impact research, positioning him as a leader in respiratory medicine, oncology, and translational research with a strong focus on innovation and clinical application.

Experience

Dr. Hongru Li has accumulated extensive clinical and academic experience at Fujian Provincial Hospital, where he has advanced through progressive leadership roles in respiratory and critical care medicine. Starting as a resident doctor, he gained experience in managing complex respiratory cases, developing proficiency in critical care interventions. He then served as an attending doctor, where he refined his clinical judgment and mentored junior staff. His expertise led to his appointment as Associate Chief Physician, where he oversaw specialized clinical programs and research initiatives. Currently, as Chief Physician, Dr. Li leads the Department of Respiratory and Critical Care Medicine, managing advanced patient care, research collaborations, and clinical training. His responsibilities span from clinical decision-making to developing research projects funded by provincial and national agencies. With deep involvement in translational research, he bridges laboratory discoveries with real-world patient care, positioning him as both a skilled clinician and an innovative medical researcher.

Awards and Honors

Dr. Hongru Li has been recognized for his exceptional contributions to clinical medicine, research innovation, and academic excellence. Early in his career, he received the Excellent Graduate Award and Excellent Postgraduate Award from Fujian Medical University, reflecting his academic dedication and professional promise. His trajectory of excellence was further reinforced with the prestigious Outstanding Youth Respiratory Scholar Award for Clinical Innovation in China, acknowledging his groundbreaking research and leadership in respiratory medicine. These honors underscore his commitment to advancing lung cancer research, patient care, and translational medicine. His ability to secure competitive research funding and lead innovative studies further reflects his recognition as a trusted expert in his field. In addition, his patents and numerous peer-reviewed publications highlight the impact of his scientific contributions. These accolades collectively demonstrate not only his academic excellence but also his role as a leading physician-researcher shaping the future of respiratory and oncology medicine.

Research Focus

Dr. Hongru Li’s research centers on the molecular mechanisms driving lung cancer progression and metastasis, with particular emphasis on brain and bone metastases in non-small cell lung cancer. He explores signaling pathways, genetic susceptibility, and the role of lipids and ceramide metabolism in tumor development. His studies have investigated proteins such as livin, RPTOR, and ceramide synthase in regulating tumor proliferation, apoptosis, and metastatic spread. Through innovative approaches, including nanoliposome-based therapies, he seeks to inhibit cancer metastasis and improve treatment responses. He has also examined genetic polymorphisms and signaling cascades, such as the PI3K/AKT/mTOR and Wnt pathways, to understand cancer susceptibility and therapy resistance. His translational research aims to transform laboratory findings into clinical applications, offering new diagnostic biomarkers and therapeutic targets. Supported by national and provincial grants, his work significantly contributes to advancing precision medicine, improving survival, and developing novel treatment strategies for patients with lung cancer.

 

Publications

 

Title: KLF9 Inhibits Brain Metastasis of Non‐Small Cell Lung Cancer by Regulating Ceramide Synthase 1 Synthesis
Year: 2025

Title: Efficacy of Prophylactic Cranial Irradiation in Early to Mid-stage Small Cell Lung Cancer Patients in the Era of Magnetic Resonance Imaging
Year: 2024

Title: Development and validation of a nomogram model based on blood-based genomic mutation signature for predicting the risk of brain metastases in non-small cell lung cancer
Year: 2024

Title: Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae
Year: 2024

Title: Clinical application value of metagenome next-generation sequencing in pulmonary diffuse exudative lesions: a retrospective study
Year: 2024

Title: Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib
Year: 2024

Title: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
Year: 2024

Conclusion

Dr. Hongru Li exemplifies the integration of clinical expertise and research innovation, dedicated to advancing respiratory and cancer medicine through groundbreaking studies, translational discoveries, and compassionate patient care.

Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Dr. Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Commonwealth Scientific and Industrial Research Organisation | Australia

Dr. Michela Simone is a distinguished scientist with expertise spanning green chemistry, renewable energy, carbohydrate chemistry, glycobiology, ionic liquids, spectroscopy, medicinal chemistry, and synthetic developments. With a multicultural background and fluency in multiple languages, she has built a global research profile, contributing significantly to sustainability and pharmaceutical sciences. Currently serving as a Research Scientist at CSIRO in Australia, she leads and supports projects focused on sustainable carbon technologies and carbon capture efficiency. Her earlier career included leadership as a CERC Fellow at CSIRO, lecturer roles at the University of Newcastle and University of Sydney, and postdoctoral research at the University of Oxford and University College London. She has published extensively in high-impact journals, authored book chapters, and holds patents in hydrogen production and drug development. Her academic and industrial collaborations highlight her interdisciplinary approach, bridging fundamental research with applied solutions to address pressing global challenges in energy, health, and sustainability.

Profile

Google scholar

ORCID

Education

Dr. Michela Simone earned her Doctor of Philosophy from the University of Oxford, where she conducted pioneering research on branched sugar lactones under the mentorship of Professor George W. J. Fleet at the Dyson Perrins Laboratory and Chemistry Research Laboratory. Prior to this, she completed her Master of Science with first-class honours at the Victoria University of Manchester, focusing on the synthesis of muscarinic receptor agonists under Professor E. James Thomas. During her studies, she was awarded a European Union Socrates Award for an exchange program at the Georg-August University of Göttingen in Germany, where she worked on chemical and biological syntheses of pyripyropenes under Professor Uwe Beifuss. This international academic training provided her with a strong foundation in synthetic organic chemistry, carbohydrate chemistry, and medicinal chemistry. Her educational journey laid the groundwork for her later achievements in spectroscopy, drug discovery, and renewable energy research, demonstrating her ability to bridge chemistry with interdisciplinary applications.

Experience

Dr. Michela Simone’s professional journey reflects a balance of academic scholarship, research innovation, and industrial collaboration. Currently, she works at CSIRO as a Research Scientist in the Sustainable Carbon Technologies Group, where she applies her mechanistic and spectroscopic expertise to optimize carbon capture processes for industrial applications. Previously, as a CERC Fellow at CSIRO, she led a major project on sustainable hydrogen production, integrating physical chemistry, engineering, and physics, resulting in a patent for water-splitting processes. Her academic career includes tenure as a Lecturer in Medicinal Chemistry and Chemical Biology at the University of Newcastle, where she managed a 40:40:20 workload across research, teaching, and service while supervising her research group in glycobiology and synthetic chemistry. Earlier, she was a Lecturer in Chemistry at the University of Sydney, focusing on medicinal and biological chemistry. Her postdoctoral work at Oxford and University College London contributed to advances in protein interactions and medicinal chemistry.

Awards and Honors

Dr. Michela Simone’s career has been marked by recognition for her contributions to chemistry and interdisciplinary research. She has authored more than sixty-five peer-reviewed publications, invited book chapters, and holds patents in hydrogen production technologies and drug delivery systems, reflecting her innovative impact on both energy and healthcare. Her invited contributions to special issues in journals such as Molecules, Pharmaceuticals, and the European Journal of Medicinal Chemistry highlight her status as a recognized expert in boron chemistry, glycobiology, and green synthetic methods. She has been invited to contribute book chapters with leading publishers including Taylor & Francis, underscoring her international reputation. Her work has been spotlighted in editorial features such as “Women in Bioorganic Chemistry,” reflecting her role as a leader and role model in science. With a growing citation record, high h-index, and strong collaborations across academia and industry, she continues to be acknowledged for her research excellence and scientific leadership.

Research Focus

Dr. Michela Simone’s research focus lies at the intersection of green chemistry, renewable energy, and medicinal chemistry, with an emphasis on practical applications that address urgent global challenges. She has pioneered work in renewable fuels, including hydrogen generation, biomass conversion, carbon capture and storage, and redox flow batteries, aiming to reduce environmental impact while improving energy efficiency. Her work in carbohydrate chemistry and glycobiology has contributed to the development of high and low Fsp3 drug leads, with innovative approaches incorporating organic boron as a novel pharmacophore for medicinal chemistry and cancer therapies. She has also advanced the field of ionic liquids, exploring their potential in sustainable synthesis and material applications. Utilizing spectroscopy and mechanistic insights, she combines fundamental chemical principles with applied solutions, leading to patents and industrial collaborations. Her interdisciplinary approach integrates chemistry, physics, and engineering, establishing her as a global leader in research that bridges sustainability, energy innovation, and health.

 

Publications

 

Title: Endothelial C-type natriuretic peptide maintains vascular homeostasis
Year: 2014
Citation: 187

Title: The expanding utility of continuous flow hydrogenation
Year: 2015
Citation: 144

Title: Synchrotron based NEXAFS study on nitrogen doped hydrothermal carbon: Insights into surface functionalities and formation mechanisms
Year: 2017
Citation: 126

Title: A compendium of sugar amino acids (SAA): scaffolds, peptide-and glyco-mimetics
Year: 2007
Citation: 121

Title: Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis
Year: 2016
Citation: 111

Title: A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues
Year: 2013
Citation: 103

Title: Kiliani on ketoses: branched carbohydrate building blocks from D-fructose and L-sorbose
Year: 2004
Citation: 87

Title: Kiliani reactions on ketoses: branched carbohydrate building blocks from D-tagatose and D-psicose
Year: 2005
Citation: 79

Title: o-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity
Year: 2019
Citation: 52

Conclusion

Dr. Michela Simone is an accomplished scientist whose interdisciplinary expertise in green chemistry, renewable energy, carbohydrate chemistry, and medicinal chemistry has led to impactful research, patents, and collaborations that advance sustainability and healthcare innovation worldwide.